Innovative Clinical Trial Designs: What’s Possible Today

Clinical trial design has changed substantially over the past decade. Methods once considered exploratory or niche are now well-established, supported by regulatory guidance, and routinely used to make development programs faster, smaller, and more informative. This session gives a non-technical overview of the design innovations that biotech teams planning or running trials should know about: what they do, when they help, and where their limitations lie.

Three Takeaways

• Discover how Bayesian innovation is transforming early-phase trials through stronger control arms, reduced placebo exposure, and more reliable dose selection.
• Increase your confidence in dose-selection decisions with regulatory-endorsed model-based approaches such as MCP-Mod, helping extract deeper insight from dose–response data and carry the right dose into Phase III.
• Explore how adaptive trial designs can increase flexibility and efficiency in clinical development, enabling earlier decisions on success or futility and more effective patient allocation.

Speakers

TBD

Agenda

11:45 Welcoming and lunch

12:00 Knowledge sharing presentation and Q&A

13:00 Mingling with coffee

About Metronomia

Metronomia about itself: Metronomia exists to elevate clinical decision-making through the power of data. As a specialist biometrics CRO, we combine more than 35 years of expertise in data management, biostatistics, statistical programming, and medical writing to support every stage of clinical development. With deep scientific knowledge, regulatory rigor, and a collaborative approach, we help sponsors strengthen clinical evidence and accelerate approval pathways.